PepGen (PEPG) Income towards Parent Company (2021 - 2026)
PepGen (PEPG) reported Income towards Parent Company of -$17.8 million for Q1 2026, up 41.19% on a YoY basis from -$12.6 million in Q1 2025, and up 2.89% sequentially from -$18.3 million in Q4 2025.
PepGen (PEPG) Income towards Parent Company (2021 - 2026) Analysis & Trends
PepGen (PEPG) has 6 years of Income towards Parent Company data on file, last reported at -$17.8 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 41.19% year-over-year to -$17.8 million; the trailing twelve-month figure through Mar 2026 stood at -$77.2 million (up 24.92% YoY), and the FY2025 full-year result was -$89.7 million, changed 0.36% from the prior year.
- Income towards Parent Company improved to -$17.8 million in Q1 2026, from -$18.3 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$16.3 million in Q1 2023 to a low of -$46.3 million in Q4 2022.
- A 5-year average of -$22.2 million and a median of -$19.4 million in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company slumped 4709.24% in 2022 and surged 58.06% in 2023, its largest moves.
- Tracing PEPG's Income towards Parent Company over 5 years: stood at -$46.3 million in 2022, then surged by 58.06% to -$19.4 million in 2023, then declined by 17.7% to -$22.9 million in 2024, then gained by 19.98% to -$18.3 million in 2025, then grew by 2.89% to -$17.8 million in 2026.
- Business Quant data shows PEPG's Income towards Parent Company at -$17.8 million in Q1 2026, -$18.3 million in Q4 2025, and -$18.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn |
| 10 | PepGen | 132.31 Mn | 132.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.76 Mn |
| Dec 31, 2025 | -18.29 Mn |
| Sep 30, 2025 | -18.03 Mn |
| Jun 30, 2025 | -23.09 Mn |
| Mar 31, 2025 | -30.20 Mn |
| Dec 31, 2024 | -22.86 Mn |
| Sep 30, 2024 | -21.38 Mn |
| Jun 30, 2024 | -28.34 Mn |
| Mar 31, 2024 | -18.02 Mn |
| Dec 31, 2023 | -19.42 Mn |
| Sep 30, 2023 | -23.29 Mn |
| Jun 30, 2023 | -19.52 Mn |
| Mar 31, 2023 | -16.32 Mn |
| Dec 31, 2022 | -46.31 Mn |
| Sep 30, 2022 | -18.63 Mn |
| Jun 30, 2022 | -17.30 Mn |
| Mar 31, 2022 | -18.25 Mn |
| Dec 31, 2021 | -963,000.00 |
| Sep 30, 2021 | -8.11 Mn |
| Jun 30, 2021 | -5.39 Mn |